MAPT and amyloidosis: Only for plasma p-tau181, tau pathology measured by tau-PET had a significantly higher contribution than amyloid pathology measured by CSF Aβ42/40, but the contribution of the Aβ marker, in this case, was not negligible (Aβ = 18%, tau = 39.7%).